eNOS knockout mice with advanced diabetic nephropathy have less benefit from renin-angiotensin blockade than from...

Area of Science:

• Nephrology
• Endocrinology
• Cardiovascular Research

Background:

• Diabetic nephropathy affects millions globally, with some patients responding poorly to renin-angiotensin system (RAS) blockade.
• Endothelial nitric oxide (NO) plays a crucial role in renal health and vascular function.
• Impaired NO bioavailability is implicated in the progression of diabetic kidney disease.

Purpose of the Study:

• To investigate the impact of impaired endothelial NO production on the efficacy of RAS blockade in diabetic nephropathy.
• To compare the renoprotective effects of RAS inhibitors in diabetic eNOS knockout (KO) mice versus wild-type mice.
• To evaluate the role of aldosterone in mediating renal injury in this context.

Main Methods:

• Utilized diabetic eNOS knockout (KO) mice and diabetic wild-type mice.
• Administered RAS inhibitors (enalapril, telmisartan) and an aldosterone antagonist (spironolactone).
• Assessed renal injury, blood pressure, and serum aldosterone levels.

Main Results:

• RAS blockade was less effective in reducing renal injury in diabetic eNOS KO mice compared to wild-type mice.
• Blood pressure reduction was transient in diabetic eNOS KO mice treated with RAS inhibitors.
• Serum aldosterone levels paradoxically increased with RAS blockade in diabetic eNOS KO mice, but decreased in wild-type mice.
• Spironolactone significantly reduced blood pressure and renal injury in diabetic eNOS KO mice.

Conclusions:

• Impaired endothelial NO production significantly diminishes the renoprotective benefits of RAS inhibition in diabetic nephropathy.
• Aldosterone may play a critical pathogenic role in diabetic kidney disease when NO signaling is compromised.
• Aldosterone blockade represents a promising therapeutic strategy for patients with diabetic nephropathy and impaired NO response.